| Authors: |
Bergemann R; 1 GlaxoSmithKline, Brentford, Middlesex, UK.; 2 Current affiliation: Evalueserve Life Sciences Healthcare, London, UK., Allsopp J; 3 Scientific Computing Group, Sheffield Teaching Hospitals Foundation Trust, Sheffield, UK., Jenner H; 4 IQVIA, London, UK., Daniels FA; 4 IQVIA, London, UK., Drage E; 4 IQVIA, London, UK., Samyshkin Y; 1 GlaxoSmithKline, Brentford, Middlesex, UK., Schmitt C; 1 GlaxoSmithKline, Brentford, Middlesex, UK., Wood S; 3 Scientific Computing Group, Sheffield Teaching Hospitals Foundation Trust, Sheffield, UK.; 5 Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK., Kiely DG; 5 Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK.; 6 National Pulmonary Hypertension Service (Sheffield), Sheffield Pulmonary Vascular Unit, Royal Hallamshire Hospital, Sheffield, UK.; 7 INSIGNEO, University of Sheffield, Sheffield, UK., Lawrie A; 5 Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK.; 7 INSIGNEO, University of Sheffield, Sheffield, UK. |
